Skip to main content
. 2024 Mar 7;79(5):glae077. doi: 10.1093/gerona/glae077

Table 1.

Baseline Characteristics of Decliners (n = 8) and Non-decliners (n = 12)

N Overall
(N = 20)
Evolution of MMSE
No decline
(N = 12)
Decline
(N = 8)
p Value
Age (y), mean (SD) 20 77.0 (5.4) 78.3 (5.3) 74.9 (5.0) .153
Female, n (%) 20 10 (50%) 6 (50%) 4 (50%) 1.000
Education, n (%)
 No diploma or primary certificate 19 5 (26%) 3 (27%) 2 (25%) .921
 Secondary education 6 (32%) 4 (36%) 2 (25%)
 High school diploma 3 (16%) 1 (9%) 2 (25%)
 University level 5 (26%) 3 (27%) 2 (25%)
Comorbidities, n (%)
 Asthma/COPD 20 1 (5%) 0 (0) 1 (13%) .400
 Diabetes 3 (15%) 2 (17%) 1 (13%) 1.000
 Hypertension 10 (50%) 5 (42%) 5 (63%) .650
 Hypercholesterolemia 10 (50%) 5 (42%) 5 (63%) .650
 Ischemic heart disease 3 (15%) 1 (8%) 2 (25%) .537
 Stroke 1 (5%) 0 (0) 1 (13%) .400
 Heart failure 0 (0) 0 (0) 0 (0)
 Active cancer 0 (0) 0 (0) 0 (0)
BMI (kg/m2), mean (SD) 20 25.7 (2.6) 26.1 (2.7) 25.1 (2.5) .375
GDS score (0–15), mean (SD) 20 3.1 (2.3) 3.3 (2.9) 2.9 (1.2) .938
MMSE score (0–30), mean (SD) 20 27.0 (1.6) 26.9 (1.5) 27.1 (1.8) .665
FCSRT score, mean (SD)
 Free recall (0–48) 20 26.8 (6.4) 28.1 (4.6) 24.9 (8.4) .438
 Total recall (0–48) 20 45.8 (3.9) 46.8 (1.2) 44.1 (5.9) .219
 Delayed free recall (0–16) 20 9.8 (2.6) 10.3 (2.0) 9.1 (3.3) .350
 Delayed total recall (0–16) 20 15.6 (1.1) 15.8 (0.4) 15.1 (1.7) .284
TMT Part A, mean (SD) 20 48.7 (12.4) 47.0 (13.4) 51.3 (11.2) .462
TMT Part B, mean (SD) 20 122.5 (36.4) 121.3 (33.3) 124.3 (43.1) .908
WAIS-R, mean (SD) 20 33.1 (5.7) 33.2 (6.4) 32.9 (4.9) .938
COWAT score, mean (SD) 20 18.7 (5.3) 18.5 (6.5) 19.0 (3.3) .816
CNT score, mean (SD) 20 24.5 (6.5) 26.1 (6.6) 22.1 (5.8) .245
CDR score, n (%)
 Score 0 20 8 (40%) 4 (33%) 4 (50%) .648
 Score 0.5 12 (60%) 8 (67%) 4 (50%)
SPPB score (0–12), mean (SD) 19 10.2 (1.6) 9.7 (1.8) 10.8 (1.0) .234
Gait speed (m/s), mean (SD) 19 1.0 (0.3) 1.0 (0.3) 1.0 (0.3) .772
Chair stand time (sec), mean (SD) 19 10.9 (3.4) 11.8 (3.6) 9.8 (3.0) .173
Balance test (0–4), mean (SD) 20 3.4 (0.9) 3.3 (1.1) 3.6 (0.7) .440
Handgrip strength (kg), mean (SD) 18 28.8 (11.6) 29.4 (10.1) 27.5 (15.2) .606
Fried frailty phenotype, n (%)
 Robust (0/5) 17 8 (47%) 6 (55%) 2 (33%) .620
 Pre-frail (1–2/5) 9 (53%) 5 (45%) 4 (67%)
 Frail (≥3/5) 0 (0) 0 (0) 0 (0)
APOE status
 ε2 17 0 (0) 0 (0) 0 (0) .762
 ε2/ε3 1 (6%) 1 (10%) 0 (0)
 ε2/ε4 0 (0) 0 (0) 0 (0)
 ε3 11 (65%) 7 (70%) 4 (57%)
 ε3/ε4 5 (29%) 2 (20%) 3 (43%)
 ε4 0 (0) 0 (0) 0 (0)
APOE ε4 carrier (ε2/ε4, ε3/ε4, ε4), n (%) 17 5 (29%) 2 (20%) 3 (43%) .593
Cortical SUVR, mean (SD) 12 1.34 (0.16) 1.27 (0.17) 1.41 (0.14) .298
SUVR positive (≥1.17), n (%) 12 10 (83%) 4 (67%) 6 (100%) .455
Plasma amyloid-beta, mean (SD) 20 0.10 (0.01) 0.10 (0.01) 0.10 (0.01) .557
Follow-up length (y) 20 4.3 (1.3) 4.7 (0.8) 3.6 (1.6) .094

Notes: APOE = Apolipoprotein E; BMI = body mass index; CDR = Clinical Dementia Rating scale; CNT = Category Naming Test; COPD = chronic obstructive pulmonary disease; COWAT = Controlled Oral Word Association Test; FCSRT = Free and Cued Selective Reminding Test; GDS = Geriatric Depression Scale; MAPT = Multidomain Alzheimer Preventive Trial; MMSE = Mini Mental State Examination; SD = standard deviation; SPPB = Short Physical Performance Battery; SUVR = standard uptake value ratio; TMT = Trail Making Test; WAIS-R = Wechsler Adult Intelligence Scale-Revised.

p Values determined using Fisher’s exact test for categorical variables or using Mann–Whitney U test for continuous variables.